Cargando…
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor
The PI3K/AKT pathway plays an important role in the initiation and progression of cancer, and the drug development efforts targeting this pathway with therapeutic interventions have been advanced by academic and industrial groups. However, the clinical outcome is moderate. Combination of inhibition...
Autores principales: | Yu, Yi, Hall, Terence, Eathiraj, Sudharshan, Wick, Michael J., Schwartz, Brian, Abbadessa, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5404396/ https://www.ncbi.nlm.nih.gov/pubmed/28240679 http://dx.doi.org/10.1097/CAD.0000000000000486 |
Ejemplares similares
-
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
por: Hall, Terence G., et al.
Publicado: (2016) -
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
por: Yu, Yi, et al.
Publicado: (2015) -
In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy
por: Wang, Jianxun, et al.
Publicado: (2017) -
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017) -
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
por: Papadopoulos, K P, et al.
Publicado: (2017)